Human Therapeutic Cells Secreting Nerve Growth Factor

• US 20080286323A1
• Filed: 01/18/2005
• Published: 11/20/2008
• Est. Priority Date: 01/19/2004
• Status: Abandoned Application

• Current Assignee: Nsgenee A/S
• Original Assignee: NsGene A/S
• Inventors: Wahlberg, Lars, Kusk, Phillip, Tornoe, Jens
• Application Number:
  US10/585,811
• Publication Number:
  US 20080286323A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61K 2035/126 Immunoprotecting barriers, e.g. jackets, diffusion chambers
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: C07K 14/48 Nerve growth factor [NGF]
• CPC Class Codes: C07K 2319/02 containing a signal sequence
• CPC Class Codes: C12N 2510/02 Cells for production
• CPC Class Codes: C12N 2510/04 Immortalised cells

Abstract

The present invention relates to human cell lines genetically modified to overexpress bioactive NGF. In another aspect the present invention relates to encapsulated human cell lines genetically modified to overexpress bioactive NGF, which can be used in therapy of Alzheimer'"'"'s disease, peripheral neuropathy and other neurological disorders amenable to local and prolonged NGF therapy.

Claims

1. A human cell line comprising a stably integrated expression construct comprising the following sequences:

a mammalian promoter,

a coding sequence operably linked to said promoter, wherein said coding sequence codes for NGF, and

an intron located in the transcript.

2. The cell line according to claim 1, wherein the cell line is a monoclonal cell line.

3. The cell line of claim 1, wherein the cell line is polyclonal cell line.

4. The cell line of claim 1, wherein the cell line is a primary culture.

5. The cell line of claim 1, wherein the cell line has not been immortalized by insertion of a heterologous immortalization gene.

6. The cell line of claim 1, wherein the cell line is contact-inhibited.

7. The cell line of claim 1 wherein the cell line is tumorigenic in mammals.

8. The cell line of claim 1, wherein the cell line is able to survive at low oxygen tension.

9. The cell line of claim 1, wherein the cell line originates from a primary culture.

10. The cell line of claim 1, wherein the cell line is capable of undergoing at least 50 doublings.

11. The cell line of claim 1, wherein the cell line triggers a low level of human host immune reaction.

12. The cell line of claim 1, further comprising a suicide construct under the control of an inducible promoter, a constitutive promoter, or a combination thereof.

13. The cell line of claim 1, further comprising a construct comprising a promoter operatively linked to a polynucleotide sequence encoding a fusion protein comprising an immunostimulatory cell surface protein linked at the amino terminus to a second cell surface polypeptide, wherein the second cell surface polypeptide comprises a transmembrane region, wherein upon expression, the fusion protein is expressed on the cell surface.

14. The cell line of claim 13, wherein the immunostimulatory cell surface polypeptide activates phagocytes but does not fix complement.

15. The cell line of claim 13, wherein the immunostimulatory cell surface polypeptide is a region of IgG.

16. The cell line of claim 13, wherein the second cell surface polypeptide is a transferrin receptor hinge region.

17. The cell line of claim 1, wherein the intron is less than 10,000 bp long.

19. The cell line of claim 1, wherein the intron is more than 50 bp long.

20. The cell line of claim 1, wherein said intron is of eukaryotic origin.

21. The cell line of claim 20, wherein said intron is of mammalian origin.

22. The cell line of claim 21, wherein said intron is of rodent origin.

23. The cell line of claim 21, wherein said intron is of primate origin.

24. The cell line of claim 21, wherein said intron is of human origin.

25. The cell line of claim 1, wherein said intron is placed in the 5′

UTR of the transcript.

26. The cell line of claim 1, wherein said intron is placed inside the sequence coding for NGF.

27. The cell line of claim 26, wherein the intron is placed in the part of the coding sequence closest to the start codon.

28. The cell line of claim 1, wherein said intron is derived from a first intron.

29. The cell line of claim 1, wherein said intron is an insulin intron or comprises a sequence having at least 95% sequence identity to bases no. 747-865 of SEQ ID No 22.

30. The cell line of claim 1, wherein said intron is an intron from the pCI vector (bases no 890 to 1022 of SEQ ID No 14) or comprises a sequence having at least 95% sequence identity to bases no 890 to 102 of SEQ ID No 14.

31. The cell line of claim 1, wherein said intron is a ubiquitin promoter intron or comprises a sequence having at least 95% sequence identity to bases no 736-1547 of SEQ ID No 20.

32. The cell line of claim 1, wherein said intron is an EF1alpha intron (bases no 609-1551 of SEQ ID No 18) or comprises a sequence having at least 95% sequence identity to bases no 609-1551 of SEQ ID No 18.

33. The cell line of claim 1, wherein the sequence coding for NGF comprises a sequence coding for a functional NGF propeptide having at least 80% sequence identity to the prodomain of SEQ ID No. 2.

34. The cell line of claim 1, wherein the sequence coding for NGF comprises a sequence selected from the group consisting of:

(a) human betaNGF coding sequence (SEQ ID No

     1);

(b) rat, mouse, or pig betaNGF (preproNGF) coding sequence;

(c) chimpanzee betaNGF (preproNGF) coding sequence;

(d) a sequence coding for mature human (SEQ ID No

     2), rat (SEQ ID No

     4), mouse (SEQ ID No

     3), pig (SEQ ID No

     6) or chimpanzee betaNGF (SEQ ID No

     5); and

(e) a sequence coding for bioactive NGF variant comprising a mature sequence having at least 80% sequence identity to the mature part of SEQ ID No 2.

35. The cell line of claim 34, wherein said bioactive NGF variant has at least 80% sequence identity to the mature part of SEQ ID No 2.

36. The cell line of claim 1, wherein the NGF coding sequence comprises the sequence coding for mature human beta NGF coding sequence.

37. The cell line of claim 1, wherein the NGF coding sequence comprises a sequence coding for mature human NGF (mature part of SEQ ID No 2).

38. The cell line of claim 1, wherein the NGF coding sequence codes for an NGF molecule wherein the mature part is selected from the group consisting of:

(a) a mature NGF molecule wherein the 25-35 region is replaced by the 25-35 region from BDNF;

(b) a mature NGF molecule wherein the 94-98 aa region is replaced by the 94-98 region from BDNF;

(c) a mature NGF molecule wherein the 23-33 region is replace by the 21-33 region from BDNF;

(d) a mature NGF molecule wherein the 92-101 region is replaced by the 92-101 region from BDNF;

(e) a mature NGF molecule wherein one or more positively charged amino acids in amino acids 30-34 and/or 94-98 are replaced by uncharged or negatively charged amino acids;

(f) a modified mature NGF molecule with reduced ability to bind p75^NGFR;

(g) a modified mature NGF molecule having amino acid substitutions at positions;

G23, H84 and either V18 or V20; and

(h) a modified mature NGF molecule comprising at least the N-terminal 117 amino acids of mature NGF and having amino acid substitutions at positions G23, H84, v18 and V20 and either H84 or T81.

39. The cell line of claim 1, wherein the NGF coding sequence codes for mature NGF with a heterologous signal peptide.

40. The cell line of claim 1, wherein the NGF coding sequence codes for a mature NGF with a heterologous pro-peptide.

41. The cell line of claim 1, wherein the stably integrated construct further comprises a sequence selected from the group consisting of:

Kozak consensus sequence, WPRE, β

-globin insulator, SP163 enhancer, non-translated 5′

or 3′

prime regions from the tau, TH of and APP genes.

42. The cell line of claim 1, where the promoter is a constitutive promoter.

43. The cell line of claim 42, wherein said promoter is selected from the group consisting of CMV, human UbiC, JeT, RSV, and EF-1alpha.

44. The cell line of claim 1, where the promoter is an inducible promoter.

45. The cell line of claim 44, where the inducible promoter is selected from the group consisting of Tet-regulatable promoter, Mo-MLV-LTR, Mx1, progesterone, and RU486.

46. The cell line of claim 1, wherein the stably integrated construct is a mammalian plasmid expression vector.

47. The cell line of claim 46, wherein said expression vector is selected from the group consisting of:

pCI, pSI, pNS, and pUbi1z.

48. The cell line of claim 1, wherein said stably integrated construct is a virus vector.

49. The cell line of claim 48, wherein said virus vector is derived from the Retroviridae family including lentivirus, HIV, SIV, FIV, EAIV, or CIV.

50. The cell line of claim 48, wherein said virus vector is selected from the group consisting of alphavirus, adenovirus, adeno associated virus, baculovirus, HSV, coronavirus, Bovin papiloma virus, and Mo-MLV.

51. The cell line of claim 1, wherein the cell line is derived from an epithelial cell.

52. The cell line of claim 51, wherein the cell line is derived from a retinal pigment epithelial (RPE) cell or a primary RPE cell.

53. The cell line of claim 52, wherein the cell line is an ARPE-19 derived cell line.

54. The cell line of claim 53, having accession number DSM ACC2706.

55. The cell line of claim 53, having accession number DSM ACC2707.

56. The cell line of claim 1, wherein the cell line is selected from the group consisting of:

astrocyte cell lines, human mesencephalic cell line, and human endothelial cell line, and wherein the cell line is immortalized with SV40T or vmyc.

57. The cell line of claim 1, wherein the cell line is able to maintain the production of a biologically active NGF at a level sufficient to maintain its useful biological activity for a period greater than one month.

58. The cell line according to claim 1, wherein the cell line is capable of secreting in excess of 0.5 ng biologically active NGF per 10⁵ cells per 24 hours.

59. An implantable cell culture device, the device comprising:

(a) a semipermeable membrane permitting the diffusion of NGF therethrough; and

(b) a population of cells from the cell line according to claim 1 disposed within the semipermeable membrane.

60. The device of claim 59, wherein the device is capable of secreting in excess of 0.1 ng biologically active NGF per 24 hours.

61. The device of claim 60, wherein the amount of biologically active NGF per 24 hours is at least 0.5 ng.

62. The device of claim 59, comprising cells obtainable from the cell line having accession number DSM ACC2706.

63. The device of claim 59, comprising cells obtainable from the cell line having accession number DSM ACC2707.

64. The device of claim 59, wherein the semipermeable membrane is immunoisolatory.

65. The device of claim 59, wherein the semipermeable membrane is microporous.

66. The device of claim 65, wherein the molecular weight cutoff of the membrane is 1000 kD or less.

67. The device of claim 59, comprising at least 10³ cells.

68. The device of claim 59, wherein the volume of the device is volume 1-10 μ

L.

69. The device of claim 59, wherein the length of the device is at least 1 mm.

70. The device of claim 59, wherein thickness of the jacket is up to 1000 μ

m depth.

71. The device of any claim 59, wherein the thickness of the jacket is 2-200 microns.

72. The device of claim 59, wherein the device further comprises a tether anchor.

73. The device of claim 59, wherein the device comprises a core comprising a reticulate foam scaffold having interconnected pores, the pore density of the foam varying between 20% and 90%, the cells being dispersed in the pores.

74. The device of claim 73, wherein the foam scaffold is a thermoplastic or a thermoplastic elastomer.

75. The device of claim 73, wherein the foam scaffold is formed from a material selected from the group consisting of polysulfone, polyethersulfone, polyurethane, and polyvinyl alcohol.

76. The device of claim 73, wherein the foam scaffold has been coated with one or more extracellular matrix molecules selected from the group consisting of collagen, laminin, vitronectin, polyornithin, fibronectin, elastin, glycosaminoglycans, and proteoglycans.

77. The device of claim 73, wherein at least a portion of the foam scaffold is exposed to a non-permissive material that inhibits mammalian cell proliferation or migration.

82. A method of treatment of a neurological disorder comprising transplanting the cells of claim 1.

83. A method of treatment of a neurological disorder, comprising insertion into a subject in need thereof at least one device of claim 59.

84. The method of claim 83, wherein the neurological disorder is Alzheimer'"'"'s disease, Huntington'"'"'s disease, CNS trauma, ALS, Parkinson'"'"'s Disease, peripheral neuropathy, neuropathic pain, or other conditions characterized by necrosis or loss of central or peripheral neurons or their processes.

85. The method of claim 82, wherein the disorder is Alzheimer'"'"'s disease and the at least one device is inserted into the basal forebrain cholinergic neurons.

86. The method of claim 83, wherein the disorder is an eye disorder.

87. The method of claim 86, wherein the eye disorder is selected from the group consisting of:

diabetic retinopathy, uveitis, retinitis pigmentosa, age related macular degeneration, glaucoma, ocular neovascularisation, retinitis, and corneal wounds.

88. The method of claim 86, wherein the at least one device is inserted into the anterior chamber, posterior chamber, or vitreous of the eye

89. The method of claim 83, wherein the disorder is peripheral neuropathy.

90. The method of claim 89, wherein the at least one device is inserted intracerebroventricularly.

92. A pharmaceutical composition comprising a cell line according to claim 1 attached to a matrix.

93. The composition of claim 92, wherein the matrix is selected from the group consisting of glass;

silicon oxides;

polystyrene;

polypropylene;

polyethylene;

polyvinylidene fluoride;

polyurethane;

polyalginate;

polysulphone;

polyvinyl alcohol;

acrylonitrile polymers;

polyacrylamide;

polycarbonate;

polypentent;

nylon;

amylases;

natural and modified gelatin;

natural and modified collagen;

natural and modified polysaccharides;

dextrans;

celluloses;

agar; and

magnetite.

94. The composition of claim 92, wherein the solid matrix is coated on its external surface with factors promoting cell adhesion, growth or survival, including selected from the group consisting of cell adhesion molecules, extracellular matrix, fibronectin, laminin, collagen, elastin, glycosaminoglycans, or proteoglycans, and growth factors.

95. The composition of claim 94, wherein growth- or survival promoting factor or factors are incorporated into the matrix material.

96. The composition of claim 92, wherein the configuration of the support is spherical, cylindrical, elliptical, a flat sheet, a strip, a needle shape, or a pin shape.

97. The composition of claim 96, wherein the sphere ranges from about 10 μ

m to 1 mm in diameter.

18. (canceled)

78. (canceled)

79. (canceled)

80. (canceled)

91. The method of claim 80, wherein the cells that supply NGF protein are attached to a matrix.

81. (canceled)

98. A method of treatment of Alzheimer'"'"'s Disease, comprising administering to an individual in need thereof a composition of ARPE-19 cells transfected with a vector selected from the group consisting of pCIn.hNGF, pCInKhNGF, and pNS1n.rINSintrA-hNGF, said composition being capable of secreting a therapeutically effective amount of mature human NGF.

99. A method of treatment of Alzheimer'"'"'s Disease, comprising administering to an individual in need thereof a device, said device comprising a semipermeable membrane permitting the diffusion of human mature NGF therethrough, the device further comprising a composition of ARPE-19 cells transfected with a vector selected from the group consisting of pCIn.hNGF, pCInKhNGF, and pNS1n.rINSintrA-hNGF, said device being capable of releasing a therapeutically effective amount of mature human NGF.

100. An ARPE-19 cell line transfected with a vector selected from the group consisting of pCIn.hNGF, pCInKhNGF, and pNS1n.rINSintrA-hNGF.

101. The ARPE-19 cell line of claim 100, having accession number DSM ACC2706.

102. The ARPE-19 cell line of claim 100, having accession number DSM ACC2707.

103. A composition of ARPE-19 cells being capable of secreting in excess of 10 ng of human mature NGF/ml/24 hours, when grown in confluent cultures in serumfree medium.

104. An implantable cell device, the device comprising:

(a) a semipermable membrane permitting the diffusion of human mature NGF therethrough; and

(b) a population of ARPE-19 cells disposed within the semipermeable membrane, said device being capable of releasing in excess of 0.1 ng human mature NGF per 24 hours when grown in serumfree medium.